Tag: In.Pact

IN.PACT™ AV Access trial shows improvement in patency “for the entire...

 A trio of vascular experts including Raphaël Coscas (Paris, France), Alexandros Mallios (Paris, France) and Kate Steiner (Stevenage, UK) discuss the key findings of...

New England Journal Of Medicine publishes “outstanding” six-month IN.PACT AV Access™...

NOTE: This video is ONLY available to watch in selected countries and geographies Robert Lookstein (New York, USA; principal investigator) and Andrew Holden (Auckland,...

Endovascular late-breaking trials presented at TCT 2020

Findings from a series of late-breaking trials in the endovascular field were presented recently at TCT Connect (14–18 October, virtual), the 32nd annual scientific...

Impressions from LINC 2020: Strong clinical and economic case for widespread...

NOTE: This video is ONLY available to watch in selected countries and geographies Andrew Holden (Auckland, New Zealand), Alexandros Mallios (Paris, France), Robert Lookstein (New...

LINC 2020: High- and low-dose paclitaxel-coated balloons exhibit comparable results at...

At the 2020 Leipzig Interventional Course (28–31 January, Leipzig, Germany), Sabine Steiner (University of Leipzig, Leipzig, Germany) presented one-year results of the COMPARE-RTC of...

A panel of experts comments on IN.PACT AV ACCESS data

NOTE: This video is ONLY available to watch in selected countries and geographies   Jos van den Berg (Lugano, Switzerland) speaks to Andrew Holden (Auckland, New...

Webinar: Safety of paclitaxel devices – what does the evidence say?

 Jos van den Berg (Lugano, Switzerland), Antonio Micari (Bergamo, Italy) and Marianne Brodmann (Graz, Austria) sit down after a specially convened US FDA panel...

Patient-level analysis shows no correlation between paclitaxel and mortality—reactions from LINC

 Renowned experts expressed confidence in the continued use of paclitaxel-coated devices after independent patient-level data presented at LINC 2019 did not show correlation between...
AV access

Three-year Japanese results show IN.PACT Admiral DCB offers “consistent and durable”...

The IN.PACT Admiral drug-coated balloon (DCB; Medtronic) exhibits a consistent and durable treatment effect in “a more complex patient demographic than typically seen in...
Purple drug-coated balloon in an s shape

IN.PACT Admiral DCB receives FDA approval for long SFA lesions

Medtronic has announced that it has received US Food and Drug Administration (FDA) approval for the IN.PACT Admiral drug-coated balloon (DCB) to treat long superficial...
interim

Latest data on Lutonix and IN.PACT drug-coated balloons in AV access...

There in an increasing physician interest in exploring the role of drug-coated balloons in arteriovenous (AV) access. At the Leipzig Interventional Course (LINC; 30...

First data from head-to-head comparison of Ranger and IN.PACT drug-coated balloons...

Early data from the first randomised controlled trial to compare two drug-coated balloons (DCBs) suggest that the primary patency obtained with the Ranger DCB...

LINC 2018 data highlight IN.PACT Admiral as safe and effective treatment...

Medtronic added to its robust body of clinical evidence supporting the IN.PACT Admiral drug-coated balloon with new presentations that demonstrated durable and consistent clinical...

Results from Asia and Belgium demonstrate consistent results from Medtronic In.Pact...

New data presented at the 2017 Leipzig Interventional Course (LINC) have demonstrated strong efficacy and consistent outcomes for Medtronic’s In.Pact Admiral drug-coated balloon across...